Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 5/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901982 | 0.97 | CPB1 (0.46) | FOLH1EPHX1TGM2CPB1CPB2 | |
| SCHEMBL13057085 | 0.94 | FOLH1 (0.51) | FOLH1EPHX1TGM2SIRT1SIRT2 | |
| SCHEMBL10017794 | 0.94 | FOLH1 (0.51) | FOLH1EPHX1TGM2SIRT1SIRT2 | |
| SCHEMBL2735587 | 0.84 | FOLH1 (0.56) | FOLH1EPHX1TGM2SIRT1SIRT5 | |
| SCHEMBL10075870 | 0.84 | EPHX1 (0.47) | EPHX1SIRT1SIRT5SIRT2 | |
| SCHEMBL15975505 | 0.84 | TGM2 (0.48) | FOLH1TGM2CPB1CPB2SIRT1 | |
| SCHEMBL12737512 | 0.84 | ACHE (0.49) | FOLH1TGM2 | |
| SCHEMBL14842646 | 0.83 | C3AR1 (0.48) | FOLH1TGM2SIRT1SIRT2SMN1; SMN2 | |
| SCHEMBL14980111 | 0.83 | EPHX1 (0.46) | FOLH1EPHX1SIRT1SIRT2 | |
| SCHEMBL14842643 | 0.83 | C3AR1 (0.48) | FOLH1TGM2SIRT1SIRT2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173947-B2 | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140329990-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS (US) | 2014-11-06 | — | — | US | disclosed |
| US-20100286355-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329990-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | CD44, FGF23, PTH1R | FOLH1 58/4885EPHX1 799/4885TGM2 1059/4885 |
| US-20100286355-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | CD44, HAAO, FGF23 | FOLH1 144/4885EPHX1 682/4885TGM2 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.